- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- zonisamide SR plus olanzapine, Placebo plus olanzapine
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 9
- States / cities
- National City, California • Orange, California • San Diego, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,710
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Hallucinations
- Interventions
- functional magnetic resonance imaging
- Device
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Schizophrenia
- Interventions
- RBP-7000
- Drug
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 48
- States / cities
- Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 41 more
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
- Interventions
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Daniel Benjamin
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3,520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 43
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Interventions
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate, Body mass index, Waist and Hip circumference, Comprehensive Medication Management
- Device · Behavioral
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Duluth, Minnesota
- Conditions
- Schizophrenia
- Interventions
- Elpipodect, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Glendale, California • Marlton, New Jersey
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
- Interventions
- Wellth - Financial Incentives
- Other
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- Placebo, Luvadaxistat
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
- Conditions
- Schizophrenia
- Interventions
- ANAVEX3-71 oral capsules, Placebo oral capsules
- Drug
- Lead sponsor
- Anavex Life Sciences Corp.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Schizophrenia, Auditory Hallucinations
- Interventions
- LIFU
- Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Schizophrenia, Bipolar I Disorder
- Interventions
- Iloperidone
- Drug
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Dothan, Alabama • Little Rock, Arkansas • Denver, Colorado + 7 more
- Conditions
- Schizophrenia
- Interventions
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
- Conditions
- Schizophrenia
- Interventions
- Oxytocin, Placebo, Social Cognitive Skills Training
- Drug · Other · Behavioral
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Interventions
- risperidone
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 7
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
- Conditions
- Bipolar Disorder, Depression, Anxiety Disorders, Schizophrenia, Tourette's Syndrome, Brain Diseases
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- Not listed
- Enrollment
- 2,161 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1990 – 2017
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia
- Conditions
- Schizophrenia
- Interventions
- ziprasidone vs risperidone or olanzapine
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
- Conditions
- Schizophrenia
- Interventions
- AMG 747, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 18
- States / cities
- Anaheim, California • Cerritos, California • Culver City, California + 15 more
- Conditions
- Acute Schizophrenia
- Interventions
- Risperidone ISM 75 mg, Risperidone ISM 100 mg, Placebo of Risperidone ISM
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 20
- States / cities
- Rogers, Arkansas • Cerritos, California • Garden Grove, California + 17 more
- Conditions
- Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Schizophrenia
- Interventions
- PF-04802540, Placebo
- Drug
- Lead sponsor
- Taisho Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia
- Interventions
- paliperidone palmitate, oral risperidone
- Drug
- Lead sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Garden Grove, California • San Diego, California + 20 more
- Conditions
- Schizophrenia
- Interventions
- Not listed
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy Subjects, Schizophrenia, Parkinson Disease
- Interventions
- Oxygen-15 Water
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,039 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1993
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Schizophrenia
- Interventions
- Lurasidone, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 16 more